ObjectiveHealth, Urology of St. Louis Launch Research Partnership
A joint clinical research center based in St. Louis will provide access to investigative therapies and diagnostic tools to improve outcomes in urologic diseases.
Gilead Sciences Acquires XinThera, Adds PARP1 Inhibitors to Oncology Pipeline
The acquisition will bring several oncology assets into Gilead's pipeline, including a PARP1 inhibitor that may enter clinical trials later this year.
Bayer, Telix Pharmaceuticals Partner to Study Nubeqa in Hormone-Sensitive Prostate Cancer
Telix will supply its PSMA imaging agent Illuccix, which Bayer will use to determine if patients have at least one PSMA-positive prostate cancer lesion at baseline.
Convergent Therapeutics Raises $90M in Series A Funding
The firm will use the proceeds to develop its lead candidate, CONV01-α, a PSMA-targeted radio-antibody.
The drugmaker is hyping its recent acquisition announcement against an overall 29 percent revenue decline and 4 percent oncology sales dip during Q1 2023.